Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline 16-04-2024, 15:35

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

AACSB Opens Public Comment on 2026 Global Standards for Business Education 10-01-2026, 02:36